A New Long-Lasting RNA Treatment for Bleeding Disorders
Understanding and Controlling the Contribution of Fibrinolysis to Bleeding Using a Long-Acting Antifibrinolytic RNA Therapy
This work explores how blood clot breakdown contributes to bleeding and aims to create a new, long-acting RNA medicine to help people with bleeding disorders.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Versiti Blood Health, INC. NIH-funded |
| Lab location | 1 site (Milwaukee, United States) |
| Project ID | NIH-11132938 on NIH RePORTER |
What this research studies
For individuals with bleeding disorders or severe injuries, the body's ability to form and break down blood clots can be out of balance, leading to increased bleeding. Current medicines often aren't enough, especially for long-term prevention, because they don't last very long in the body. Our goal is to develop a new type of RNA therapy that can reduce bleeding over a longer period by targeting a key protein involved in dissolving clots. This new medicine would be delivered using a safe, clinically approved method, offering a more effective way to manage bleeding for many patients.
Who could benefit from this research
Good fit: This research is ultimately aimed at helping patients with diagnosed or undiagnosed bleeding disorders who experience increased bleeding due to issues with clot breakdown.
Not a fit: Patients whose bleeding is not primarily caused by excessive clot breakdown (fibrinolysis) may not receive direct benefit from this specific therapy.
Why it matters
Potential benefit: If successful, this new long-acting RNA therapy could provide a more effective and convenient way to prevent and manage bleeding for individuals with various bleeding disorders.
How similar studies have performed: While current antifibrinolytic drugs exist, this approach focuses on a novel long-acting RNA therapy, which represents a new direction for managing bleeding disorders.
Where this research is happening
Milwaukee, United States
- Versiti Blood Health, INC. — Milwaukee, United States (Active)
Researchers
- Principal investigator: Kastrup, Christian — Versiti Blood Health, INC.
- Study coordinator: Kastrup, Christian
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.